EGFR and neoplasm: Consequently, M2 macrophages are regarded as potential biomarkers of tumor aggressiveness and therapeutic targets, particularly in combination with HIF inhibitors, metabolic agents, or immunotherapeutic strategies targeting the EGFR/VEGFR signaling pathways [24,25].